@article {SobieckaP467, author = {Malgorzata Sobiecka and Malgorzata Bartosiewicz and Katarzyna Lewandowska and Piotr Radwan-Rohrenschef and Iwona Bestry and Renata Langfort and Jan Kus}, title = {Sarcoidosis related to interferon and ribavirin treatment of hepatitis C {\textendash} Analysis of four cases}, volume = {44}, number = {Suppl 58}, elocation-id = {P467}, year = {2014}, publisher = {European Respiratory Society}, abstract = {Sarcoidosis is a multisystem granulomatous disorder of unknown etiology. Several reports have suggested an association between antiviral treatment of hepatitis C virus (HCV) infection and sarcoidosis.Aims: To describe the main characteristics and treatment of sarcoidosis developing in patients with chronic hepatitis C receiving pegylated interferon (PEG INF) and ribavirin (RBV) therapy.METHODS: Retrospective analysis of all patients with a history of HCV treatment, who were diagnosed with sarcoidosis in our institution.RESULTS: We identified 4 patients (3 men, 1 woman, mean age 53,75 yrs; range 52 {\textendash} 55 yrs) with chronic hepatitis C who developed INF-α-induced sarcoidosis. Three patients developed pulmonary sarcoidosis following completion of treatment with PEG INF and RBV (after 3, 7 and 10 months, respectively), in one patient hepatic and pulmonary sarcoidsosis emerged during therapy. The diagnosis was confirmed by biopsy in all patients (1 {\textendash} cervical lymph node, 1- liver and 2 {\textendash} transbronchial lung biopsy). Mean follow-up period was 27,25 months (4, 26, 37 and 42 months, respectively). Stabilization without specific therapy of sarcoidosis was observed in two patients and relapse after initial spontaneous remission in one case. One patient was treated with prednisone due to symptoms (cough, dyspnea) and impairment of pulmonary function tests (restriction, decreased DLco).CONCLUSIONS: Sarcoidosis may appear during, but also upon completion of a pegylated INF-α and ribavirin therapy. A search for clinical and radiological findings typical for sarcoidosis in patients with chronic hepatitis C should be included in the follow up during and after antiviral therapy.}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/44/Suppl_58/P467}, eprint = {https://erj.ersjournals.com/content}, journal = {European Respiratory Journal} }